Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dicerna and PBL Sign Agreement for Baulcombe & Hamilton RNAi Patents

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
Dicerna Pharmaceuticals, Inc. (Dicerna) and Plant Bioscience Limited (PBL), announced that they have entered an agreement for a non-exclusive licence to PBL’s RNAi intellectual property estate.

PBL will grant Dicerna a world-wide, non-exclusive license to the Baulcombe patents (U.S. Patent Nos. 8,097,710; 8,258,285; 8,299,235 and 8,263,569) for use in the field of human therapeutics.  Financial terms were not disclosed.

“We are pleased to add the Baulcombe patents to our expanding intellectual property portfolio,” said Douglas M. Fambrough, CEO of Dicerna.  “We have continued to innovate and advance our DsiRNA and EnCore technologies, allowing us to develop innovative programs against previously undruggable targets.  Dicerna’s programs, along with those of our partners, means we are moving forward on multiple fronts to bring new options to patients via well-known and powerful mechanisms.”

PBL’s Managing Director, Dr. Jan Chojecki, stated, “We are delighted to add Dicerna as our partner in the development of RNAi therapeutics. Dicerna is currently advancing an exciting RNAi-based therapeutic oncology candidate into the development stage.  This agreement further endorses the strength of our patent estate in the RNAi field and we look forward to working with other partners in therapeutic applications, as well as in research reagents, diagnostics and of course agricultural applications of this pivotal technology.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dicerna Reports Progress with GalNAc-DsiRNA-EX-Conjugates
Dicerna has presented preclinical data suggesting the feasibility of its proprietary GalNAc-DsiRNA-EX-Conjugate technology in enabling direct delivery of RNAi-based therapy to the liver via subcutaneous (SC) or intravenous (IV) injection.
Thursday, March 03, 2016
Dicerna Announces Potent, Durable Knockdown of Gene Expression in Non-human Primates
The company, a leader in the development of RNA interference (RNAi) therapeutics, presented preclinical data demonstrating the feasibility of its proprietary DsiRNA-EX Conjugate-mediated delivery technology.
Thursday, May 07, 2015
Dicerna Pharmaceuticals Appoints Life Sciences Executive James B. Weissman to Chief Business Officer
Mr. Weissman joins Dicerna with more than 25 years in the life sciences industry and will be responsible for corporate development, strategy and other operational functions.
Thursday, January 05, 2012
Scientific News
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!